Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Hematology

• Publication date

  2017-08-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17474086.2017.1364989PMID 28817980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice

  2018cited by this paper
• Gene Therapy in a Patient with Sickle Cell Disease: Brief Report

  2017cited by this paper
• Gene Therapy in a Patient with Sickle Cell Disease.

  2017cited by this paper
• Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

  2017cited by this paper
• Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme

  2017cited by this paper
• Heme as a Target for Therapeutic Interventions

  2017cited by this paper
• Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine

  2017influential reference
• Arginine Therapy Shows Promise for Treatment of Sickle Cell Disease Clinical Subphenotypes of Hemolysis and Arginine Deficiency.

  2017cited by this paper
• Intravascular hemolysis and the pathophysiology of sickle cell disease

  2017influential reference
• Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

  2016influential reference
• Prasugrel for Sickle Cell Vaso-Occlusive Events.

  2016cited by this paper
• CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

  2016cited by this paper
• Airway hyperreactivity is frequent in non‐asthmatic children with sickle cell disease

  2016cited by this paper
• Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells

  2016cited by this paper
• Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice

  2016cited by this paper
• Prasugrel for Sickle Cell Vaso-Occlusive Events.

  2016cited by this paper
• Haematological determinants of cardiac involvement in adults with sickle cell disease.

  2016cited by this paper
• The trials and hopes for drug development in sickle cell disease

  2015cited by this paper
• Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease

  2015cited by this paper
• Vasculopathy and pulmonary hypertension in sickle cell disease.

  2015cited by this paper
• Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea

  2015cited by this paper
• Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia

  2015cited by this paper
• Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease.

  2015cited by this paper
• Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.

  2015cited by this paper
• Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease.

  2014cited by this paper
• Elevated Pulse Pressure is Associated with Hemolysis, Proteinuria and Chronic Kidney Disease in Sickle Cell Disease

  2014cited by this paper
• Erythroid DAMPs drive inflammation in SCD.

  2014cited by this paper
• Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factor.

  2014cited by this paper
• Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy.

  2014influential reference
• Hypoxic Response Contributes to Altered Gene Expression and Precapillary Pulmonary Hypertension in Patients With Sickle Cell Disease

  2014cited by this paper
• A Phase 3 Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia

  2014cited by this paper
• In vitro and in vivo anti-angiogenic effects of hydroxyurea.

  2014cited by this paper
• An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

  2014influential reference
• Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom

  2014cited by this paper
• Abnormal Pulmonary Function and Associated Risk Factors in Children and Adolescents With Sickle Cell Anemia

  2014cited by this paper
• Pulmonary hypertension in sickle cell disease.

  2014cited by this paper
• Obstructive Sleep Apnea and Sickle Cell Anemia

  2014cited by this paper
• A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes

  2013cited by this paper
• β-globin gene transfer to human bone marrow for sickle cell disease.

  2013cited by this paper
• The Kinase PDK1 Is Essential for B-Cell Receptor Mediated Survival Signaling

  2013cited by this paper
• Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure.

  2013cited by this paper
• A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease

  2013cited by this paper
• Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension

  2013cited by this paper
• A Randomized Pilot Study of L-Arginine Infusion in Severe Falciparum Malaria: Preliminary Safety, Efficacy and Pharmacokinetics

  2013cited by this paper
• Hemodynamic predictors of mortality in adults with sickle cell disease.

  2013cited by this paper
• L‐arginine as an adjuvant drug in the treatment of sickle cell anaemia

  2013cited by this paper
• Modification of Hemodynamic and Immune Responses to Exposure with a Weak Antigen by the Expression of a Hypomorphic BMPR2 Gene

  2013cited by this paper
• Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease

  2013cited by this paper
• Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease

  2012cited by this paper
• Arginases and arginine deficiency syndromes

  2012cited by this paper
• Mortality in adults with sickle cell disease and pulmonary hypertension.

  2012cited by this paper
• Multifactorial risk factor intervention in patients with Type 2 diabetes improves arginine bioavailability ratios

  2012cited by this paper
• Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine.

  2012cited by this paper
• N-acetylcysteine reduces oxidative stress in sickle cell patients

  2012cited by this paper
• Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia

  2011influential reference
• Arginase and Arginine Dysregulation in Asthma

  2011cited by this paper
• Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease

  2011cited by this paper
• Prevalence, risk factors and mortality of pulmonary hypertension defined by right heart catheterization in patients with sickle cell disease

  2011cited by this paper
• Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

  2011cited by this paper
• Contemporary Reviews in Cardiovascular Medicine Pulmonary Hypertension Associated With Hemoglobinopathies Prevalent But Overlooked

  2011cited by this paper
• A hemodynamic study of pulmonary hypertension in sickle cell disease.

  2011cited by this paper
• Predictors of Mortality in Children and Adolescents with Sickle Cell Disease: The PUSH Study

  2011cited by this paper
• Hemolysis-associated pulmonary hypertension in sickle cell disease and thalassemia

  2011cited by this paper
• Asthma and chronic sickle cell lung disease: a dynamic relationship.

  2011cited by this paper
• Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

  2011cited by this paper
• Vascular risk assessment in patients with sickle cell disease

  2011cited by this paper
• Asthma in Sickle Cell Disease

  2011cited by this paper
• Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked.

  2011cited by this paper
• Asymmetric dimethylarginine is increased in asthma.

  2011cited by this paper
• Exercise Capacity and Hemodynamics in Patients with Sickle Cell Disease with Pulmonary Hypertension Treated with Bosentan: Results of the ASSET studies

  2011cited by this paper
• Airway hyperresponsiveness in children with sickle cell anemia.

  2011cited by this paper
• Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady‐state: a nested case control study of deaths versus survivors

  2011cited by this paper
• Pulmonary hypertension in thalassemia

  2010cited by this paper
• Dysregulation of l-arginine metabolism and bioavailability associated to free plasma heme

  2010cited by this paper
• Population estimates of sickle cell disease in the U.S.

  2010cited by this paper
• Pulmonary hypertension in sickle cell disease children under 10 years of age

  2010cited by this paper
• A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers

  2010cited by this paper
• The inherited diseases of hemoglobin are an emerging global health burden.

  2010cited by this paper
• Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.

  2010cited by this paper
• Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Angiogenic and Inflammatory Markers of Cardiopulmonary Changes in Children and Adolescents with Sickle Cell Disease

  2009cited by this paper
• Hematologic, biochemical, and cardiopulmonary effects of l‐arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy

  2009cited by this paper
• Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea

  2009cited by this paper
• Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease.

  2009cited by this paper
• Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks: Potential Mechanisms Beyond Nitric Oxide Synthase Inhibition

  2009cited by this paper
• Pulmonary hypertension in sickle cell disease

  2009cited by this paper
• Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.

  2009cited by this paper
• Asthma management: Reinventing the wheel in sickle cell disease

  2009cited by this paper
• Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease.

  2008cited by this paper
• Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation

  2008cited by this paper
• Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

  2008cited by this paper
• Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

  2008cited by this paper
• Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.

  2008cited by this paper
• Methacholine challenge in children with sickle cell disease: A case series

  2008cited by this paper
• Sickle cell disease vasculopathy: a state of nitric oxide resistance.

  2008cited by this paper
• Asthma is associated with acute chest syndrome, but not with an increased rate of hospitalization for pain among children in France with sickle cell anemia: a retrospective cohort study

  2008cited by this paper
• Safety Profile of L-Arginine Infusion in Moderately Severe Falciparum Malaria

  2008cited by this paper
• Cardiac iron across different transfusion-dependent diseases.

  2008cited by this paper
• Pulmonary complications of sickle cell disease.

  2008cited by this paper

• Clinical Study to Evaluate the Possible Efficacy and Safety of l-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial

  2025influential citation
• Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension

  2023influential citation
• Arginine Therapy and Cardiopulmonary Hemodynamics in Hospitalized Children with Sickle Cell Anemia: A Prospective Double-Blinded Randomized Placebo-Controlled Trial.

  2022cites this paper
• The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells.

  2022cites this paper
• Vanillic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension by Enhancing NO Signaling Pathways

  2022cites this paper
• miR-1283 Contributes to Endoplasmic Reticulum Stress in the Development of Hypertension Through the Activating Transcription Factor-4 (ATF4)/C/EBP-Homologous Protein (CHOP) Signaling Pathway

  2021cites this paper
• An Update on Arginase Inhibitors and Inhibitory Assays.

  2021cites this paper
• Genetic modifiers of long‐term survival in sickle cell anemia

  2020cites this paper
• Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline

  2019cites this paper
• Pulmonary Hypertension

  2019cites this paper